Contact Us
TEL: +86-0571-88334626
E-mail: sales@tacon-china.com.cn
Home > News > Content
Cobimetinib CAS No.:934660-93-2 Made By Hangzhou Shitai Biotech Co.,LTD In China
Feb 13, 2018

PRODUCT NAME

Cobimetinib

CAS No.:

934660-93-2

Synonyms

[3,4-Difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl][3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl]methanone

GDC 0973;XL 518;

Formula:

C21H21F3IN3O2

Molecular Weight:

531.31000

PSA:

64.60000

LogP:

4.12080

 

Structure

Description

Cobimetinib (trade name Cotellic) is a MEK inhibitor developed by Exelixis and Genentech. It is used in combination with vemurafenib, a BRAF inhibitor, to treat melanoma. In November 2015, the U.S. Food and Drug Administration approved cobimetinib for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib (Zelboraf). Cobimetinib is not indicated for treatment of patients with wild-type BRAF melanoma.
Cobimetinib in combination with vemurafenib is reportedly priced at $17,600 per month, or about $211,000 per year. A competing dual therapy, using dabrafenib along with trametinib, is also approved by the FDA, and is reported to cost $15,300 monthly, or $183,600 per year.

We can provide this product with purity 99%.


The test result of COA

ProductName: Cobimetinib

Cas:       934660-93-2

Batch No.:    20171012

MFG Date:  Oct.12.2017

Analysis Date:Oct.12.2017

 

 

 

Inspect Item

Quantity Standard

Inspection Result

Appearance

White to light   yellow powder

White powder

Identification

Positive

Conforms

Purity

98%

99.40%

Single impurity

0.20%

0.33%

Residual solvent

0.50%

0.30%

EE value

99%

99.82%

Conclusion

In accordance with enterprise standard